8-K current report · filed Aug 6, 2026

Evolent Health, Inc. (EVH) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1EVH overview

Short answer

Evolent Health, Inc. (EVH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results announced for quarter ended June 30, 2026.

Evolent Health, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Press release contains the financial figures and management commentary, filed as Exhibit 99.1
  • Investor focus: quarterly performance, outlook, and operating trends disclosed in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $652.5M, up from $444.3M; GAAP net loss narrowed to $28.4M from $51.1M
  • Adjusted EBITDA $28.1M, down from $37.5M; margin compressed to 4.3% from 8.5%
  • Medical expense ratio rose to 95.3% from 80.0%, signaling significant pressure on Performance Suite profitability
  • 2026 guidance raised to $2.6–$2.7B revenue and tightened to $120–$135M Adjusted EBITDA
  • Oncology launch targeted by December 2026 across approximately 1.5M lives, with approximately $300M annualized revenue potential

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Evolent Health, Inc. 8-K filings

Get the next EVH 8-K as it lands

Follow EVH for push alerts, or ask the research agent what this filing means.